Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus.
about
Immunoregulation of NKT Cells in Systemic Lupus ErythematosusDisparate effects of depletion of CD1d-reactive T cells during early versus late stages of disease in a genetically susceptible model of lupus.Germline deletion of β2 microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupusChallenges in the diagnosis and management of autoimmune hepatitis.Current and prospective pharmacotherapy for autoimmune hepatitis.Cell mediators of autoimmune hepatitis and their therapeutic implications.Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.Intrinsic hyporesponsiveness of invariant natural killer T cells precedes the onset of lupus.TLR-Induced SMPD3 Defects Enhance Inflammatory Response of B Cell and Macrophage in the Pathogenesis of SLE.The Janus Face of NKT Cell Function in Autoimmunity and Infectious Diseases.Invariant NKT Cell Activation Is Potentiated by Homotypic trans-Ly108 Interactions.Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice.Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity.
P2860
Q26773074-0CFAF187-E6C5-4964-8826-21D295F55C64Q36143507-5CAE0FBA-AEB6-43D8-8C4F-A9AB3F3EDCCCQ36903316-B217CC6D-0911-44B8-BEFA-08472FBC7A71Q37640582-160F8B99-88E4-4A35-98EE-99BAF108C8A8Q38222882-38BA5A81-9EB2-4A10-B10B-485AA28E56F7Q38285331-E7D35B97-76D0-4FF4-A8CB-509514C9172EQ38496935-FE1F3FB2-C7C0-4991-9E9A-EC50B3B3B2DFQ39303557-623C14CB-7DB8-4094-9717-75CCBBBF948FQ46882098-39D95478-2539-4FDD-BF04-9BF9486B3ECEQ47826879-DD596AA8-254F-4D6D-910C-656248B68841Q48124107-C966FB44-4216-47DC-9949-3F9B803A89CFQ51073234-B501604C-628B-44DC-970E-5A4E80EB12F0Q54998990-E997F1CF-4470-43BB-8FA3-9D9211A39DC3Q55280646-98E74473-DA95-4D54-BEC2-608BD28E7F01
P2860
Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Brief treatment with iNKT cell ...... term protection against lupus.
@ast
Brief treatment with iNKT cell ...... term protection against lupus.
@en
type
label
Brief treatment with iNKT cell ...... term protection against lupus.
@ast
Brief treatment with iNKT cell ...... term protection against lupus.
@en
prefLabel
Brief treatment with iNKT cell ...... term protection against lupus.
@ast
Brief treatment with iNKT cell ...... term protection against lupus.
@en
P2093
P2860
P1476
Brief treatment with iNKT cell ...... term protection against lupus.
@en
P2093
Jun-Qi Yang
Peter J Kim
Ram Raj Singh
P2860
P2888
P304
P356
10.1007/S10875-011-9590-Y
P577
2011-10-15T00:00:00Z